trimethoprim 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibacterials, dihydrofolate reductase (DHFR) inhibitors, trimethoprim derivatives	2755	738-70-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: trimethoprim trimethoprim sulfate trimethoprim hydrochloride trimethioprim trimetoprim trimopan trimethoprim HCl	A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported. Molecular weight: 290.32 Formula: C14H18N4O3 CLOGP: 1.08 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 105.51 ALOGS: -2.67 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

trimethoprim
trimethoprim sulfate
trimethoprim hydrochloride
trimethioprim
trimetoprim
trimopan
trimethoprim HCl

A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.

Molecular weight: 290.32
Formula: C14H18N4O3
CLOGP: 1.08
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 105.51
ALOGS: -2.67
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O
0.40	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1.37 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	70 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	15.75 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	98 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.50 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	9.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 30, 1973	FDA	MUTUAL PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	177.32	10.45	252	41481	819081	49744310
Soft tissue disorder	174.46	10.45	80	41653	4134	50559257
Acute kidney injury	174.21	10.45	496	41237	227562	50335829
Liver function test abnormal	123.42	10.45	167	41566	44172	50519219
Leukopenia	107.82	10.45	197	41536	67331	50496060
Pre-engraftment immune reaction	101.25	10.45	26	41707	212	50563179
Pneumonia viral	99.62	10.45	65	41668	6769	50556622
Pancytopenia	99.12	10.45	216	41517	83814	50479577
Off label use	93.41	10.45	155	41578	474271	50089120
Hyperkalaemia	93.38	10.45	153	41580	47936	50515455
Pyrexia	91.78	10.45	581	41152	379622	50183769
Stevens-Johnson syndrome	88.13	10.45	99	41634	21653	50541738
Encephalitis viral	77.86	10.45	34	41699	1563	50561828
Product dose omission issue	71.58	10.45	31	41702	183807	50379584
Hyponatraemia	71.14	10.45	207	41526	95932	50467459
Cytomegalovirus infection	68.10	10.45	79	41654	17883	50545508
Completed suicide	66.17	10.45	14	41719	131875	50431516
Lip swelling	65.54	10.45	91	41642	24645	50538746
Human herpesvirus 6 infection	64.82	10.45	35	41698	2571	50560820
Abdominal discomfort	64.11	10.45	58	41675	231583	50331808
Systemic lupus erythematosus	62.71	10.45	19	41714	140603	50422788
Swelling face	60.62	10.45	134	41599	52461	50510930
Fatigue	60.60	10.45	340	41393	707261	49856130
Alopecia	60.24	10.45	68	41665	244979	50318412
Toxic epidermal necrolysis	58.29	10.45	79	41654	20913	50542478
Injection site pain	55.25	10.45	12	41721	111012	50452379
International normalised ratio increased	54.38	10.45	114	41619	43038	50520353
Pemphigus	54.01	10.45	16	41717	120150	50443241
Product use issue	53.88	10.45	28	41705	149447	50413944
Infusion related reaction	53.77	10.45	37	41696	169520	50393871
Maternal exposure during pregnancy	50.48	10.45	35	41698	159743	50403648
Confusional state	49.66	10.45	292	41441	185636	50377755
Kidney transplant rejection	48.73	10.45	34	41699	3953	50559438
Rheumatoid arthritis	47.83	10.45	58	41675	202492	50360899
Thrombocytopenia	47.57	10.45	220	41513	127453	50435938
Mouth swelling	46.94	10.45	33	41700	3883	50559508
Fibromyalgia	46.73	10.45	110	41623	44868	50518523
Arthropathy	45.52	10.45	38	41695	157868	50405523
Rash maculo-papular	45.40	10.45	80	41653	26561	50536830
Superinfection	43.97	10.45	25	41708	2031	50561360
Nasopharyngitis	43.72	10.45	57	41676	192870	50370521
Glossodynia	42.61	10.45	21	41712	115548	50447843
Treatment failure	42.35	10.45	31	41702	137606	50425785
Pain	42.27	10.45	292	41441	578611	49984780
Drug reaction with eosinophilia and systemic symptoms	41.68	10.45	80	41653	28344	50535047
Drug interaction	41.32	10.45	294	41439	199327	50364064
Urosepsis	41.12	10.45	57	41676	15408	50547983
Fear of eating	41.03	10.45	14	41719	326	50563065
Renal failure	40.64	10.45	185	41548	106448	50456943
Death	40.12	10.45	136	41597	325243	50238148
Hepatic cytolysis	40.08	10.45	41	41692	8062	50555329
Blood creatinine increased	40.05	10.45	146	41587	76014	50487377
Agranulocytosis	40.01	10.45	67	41666	21354	50542037
Platelet count decreased	39.32	10.45	176	41557	100550	50462841
Anaemia	39.21	10.45	348	41385	252108	50311283
Ejection fraction decreased	38.77	10.45	61	41672	18459	50544932
Deep vein thrombosis	38.10	10.45	140	41593	73164	50490227
Intentional product use issue	36.89	10.45	9	41724	76909	50486482
Blood cholesterol increased	36.21	10.45	114	41619	55101	50508290
Hypophagia	35.80	10.45	74	41659	27654	50535737
Psoriasis	35.27	10.45	7	41726	68993	50494398
Intentional overdose	34.91	10.45	5	41728	62499	50500892
Rash erythematous	34.87	10.45	84	41649	34768	50528623
Pneumocystis jirovecii pneumonia	34.51	10.45	51	41682	14612	50548779
Drug intolerance	34.02	10.45	82	41651	219022	50344369
Blood pressure increased	33.71	10.45	36	41697	133096	50430295
Oral pain	32.55	10.45	67	41666	24966	50538425
Injection site erythema	31.84	10.45	11	41722	74925	50488466
Bone marrow failure	31.39	10.45	70	41663	27554	50535837
Discomfort	31.32	10.45	26	41707	108354	50455037
Bacterial sepsis	31.17	10.45	25	41708	3587	50559804
Transplant rejection	31.09	10.45	39	41694	9570	50553821
Contraindicated product administered	30.76	10.45	47	41686	148911	50414480
Injection site reaction	30.41	10.45	3	41730	50029	50513362
Complications of transplanted kidney	30.04	10.45	20	41713	2153	50561238
Tenderness	29.39	10.45	54	41679	18511	50544880
Wound	28.62	10.45	27	41706	105767	50457624
Herpes zoster	28.61	10.45	125	41608	70661	50492730
Documented hypersensitivity to administered product	28.57	10.45	12	41721	501	50562890
Muscle twitching	28.47	10.45	48	41685	15383	50548008
Parkinsonian rest tremor	28.30	10.45	8	41725	97	50563294
HIV infection	27.78	10.45	10	41723	274	50563117
Ureteric obstruction	27.50	10.45	17	41716	1611	50561780
Neutropenic sepsis	27.43	10.45	45	41688	14102	50549289
Cholecystitis chronic	26.25	10.45	36	41697	9633	50553758
Abdominal pain	26.23	10.45	304	41429	235924	50327467
Neutropenia	26.12	10.45	210	41523	147755	50415636
Vomiting	25.95	10.45	528	41205	460230	50103161
Photophobia	25.74	10.45	45	41688	14842	50548549
Meningoencephalitis herpetic	25.56	10.45	14	41719	1058	50562333
Arthralgia	25.15	10.45	236	41497	438466	50124925
Tubulointerstitial nephritis	25.04	10.45	45	41688	15166	50548225
Suicide attempt	24.91	10.45	6	41727	51726	50511665
Synovial fluid analysis	24.90	10.45	16	41717	1622	50561769
Fall	24.82	10.45	168	41565	334764	50228627
Blindness cortical	24.30	10.45	10	41723	396	50562995
Urinary tract infection	23.86	10.45	286	41447	223734	50339657
Wrong technique in product usage process	23.84	10.45	8	41725	55502	50507889
Pericarditis	23.84	10.45	18	41715	78671	50484720
Sinusitis	23.30	10.45	68	41665	170490	50392901
Conjunctivitis	23.13	10.45	45	41688	16100	50547291
Multiple organ dysfunction syndrome	22.76	10.45	92	41641	50245	50513146
Tenosynovitis stenosans	22.69	10.45	17	41716	2207	50561184
Inappropriate schedule of product administration	22.32	10.45	16	41717	71815	50491576
Pulmonary embolism	22.30	10.45	152	41581	101552	50461839
Hand deformity	22.27	10.45	30	41703	100169	50463222
Renal tubular necrosis	21.99	10.45	34	41699	10134	50553257
Pregnancy with injectable contraceptive	21.90	10.45	7	41726	132	50563259
Drug abuse	21.86	10.45	11	41722	59835	50503556
Hepatitis fulminant	21.84	10.45	19	41714	3049	50560342
Cholelithiasis	21.84	10.45	75	41658	37898	50525493
Weight increased	21.82	10.45	89	41644	201802	50361589
Infection	21.67	10.45	228	41505	172726	50390665
Anti-cyclic citrullinated peptide antibody positive	21.57	10.45	16	41717	70571	50492820
Body mass index decreased	21.53	10.45	9	41724	371	50563020
Dehydration	21.52	10.45	206	41527	152243	50411148
Renal tubular disorder	21.31	10.45	17	41716	2420	50560971
Pseudomonas infection	21.05	10.45	32	41701	9398	50553993
Septic shock	20.88	10.45	98	41635	57077	50506314
Acquired immunodeficiency syndrome	20.70	10.45	6	41727	80	50563311
Seizure	20.64	10.45	167	41566	117707	50445684
Inappropriate antidiuretic hormone secretion	20.52	10.45	38	41695	13105	50550286
Oral candidiasis	20.51	10.45	44	41689	16871	50546520
Cystitis noninfective	20.43	10.45	11	41722	803	50562588
Injection site bruising	20.39	10.45	3	41730	36765	50526626
Bronchopulmonary aspergillosis	20.21	10.45	28	41705	7564	50555827
Foaming at mouth	19.88	10.45	12	41721	1090	50562301
Vulvovaginal candidiasis	19.83	10.45	17	41716	2675	50560716
Blood pressure fluctuation	19.69	10.45	3	41730	35820	50527571
Clostridial infection	19.39	10.45	20	41713	3970	50559421
Porphyria acute	19.21	10.45	9	41724	488	50562903
Toxicity to various agents	19.21	10.45	100	41633	212399	50350992
Scleritis	19.07	10.45	18	41715	3209	50560182
Lethargy	18.99	10.45	86	41647	49346	50514045
Pleuritic pain	18.96	10.45	25	41708	6441	50556950
Immune reconstitution inflammatory syndrome	18.83	10.45	23	41710	5493	50557898
Hospitalisation	18.77	10.45	17	41716	67920	50495471
Urine output decreased	18.67	10.45	32	41701	10389	50553002
Soft tissue swelling	18.57	10.45	11	41722	965	50562426
Aplasia pure red cell	18.48	10.45	20	41713	4195	50559196
Bacterial test positive	18.28	10.45	21	41712	4702	50558689
Alanine aminotransferase increased	18.16	10.45	130	41603	88229	50475162
Libido disorder	18.13	10.45	5	41728	55	50563336
Effusion	18.04	10.45	13	41720	1590	50561801
Injection site swelling	17.97	10.45	6	41727	41767	50521624
COVID-19	17.93	10.45	8	41725	46654	50516737
Trimethylaminuria	17.90	10.45	6	41727	132	50563259
Febrile bone marrow aplasia	17.89	10.45	24	41709	6287	50557104
Immunosuppressant drug level increased	17.85	10.45	17	41716	3065	50560326
Chemotherapeutic drug level increased	17.78	10.45	6	41727	135	50563256
Influenza	17.76	10.45	29	41704	89509	50473882
Knee arthroplasty	17.57	10.45	4	41729	35842	50527549
Arthritis	17.48	10.45	127	41606	86594	50476797
Pruritus genital	17.24	10.45	9	41724	617	50562774
Breast cancer	17.04	10.45	7	41726	42883	50520508
Meningitis aseptic	16.99	10.45	19	41714	4133	50559258
Cogwheel rigidity	16.84	10.45	13	41720	1764	50561627
Dermatitis exfoliative	16.84	10.45	21	41712	5121	50558270
Pustule	16.67	10.45	11	41722	1167	50562224
Physical assault	16.67	10.45	10	41723	898	50562493
Angiodermatitis	16.65	10.45	5	41728	76	50563315
Potentiating drug interaction	16.54	10.45	18	41715	3798	50559593
Blood alkaline phosphatase increased	16.50	10.45	68	41665	37458	50525933
Blood culture positive	16.41	10.45	19	41714	4289	50559102
Musculoskeletal stiffness	16.28	10.45	53	41680	128428	50434963
Adverse drug reaction	16.26	10.45	13	41720	55209	50508182
Aspartate aminotransferase increased	16.17	10.45	115	41618	77883	50485508
Mental status changes	16.16	10.45	66	41667	36206	50527185
Neutrophil count decreased	16.16	10.45	78	41655	45948	50517443
Palmar erythema	16.06	10.45	12	41721	1551	50561840
Antinuclear antibody	16.05	10.45	8	41725	498	50562893
Vestibular disorder	15.92	10.45	11	41722	1258	50562133
Ill-defined disorder	15.92	10.45	13	41720	54641	50508750
Jaundice	15.90	10.45	53	41680	26376	50537015
Oliguria	15.74	10.45	26	41707	8190	50555201
Purpura senile	15.71	10.45	8	41725	521	50562870
Subdural haemorrhage	15.61	10.45	15	41718	2734	50560657
Sepsis	15.60	10.45	173	41560	132752	50430639
Tarsal tunnel syndrome	15.57	10.45	8	41725	531	50562860
Loss of personal independence in daily activities	15.54	10.45	21	41712	70029	50493362
Citrobacter infection	15.53	10.45	7	41726	347	50563044
Lung transplant rejection	15.51	10.45	9	41724	760	50562631
Pseudomembranous colitis	15.45	10.45	15	41718	2770	50560621
Allergy to chemicals	15.44	10.45	11	41722	1321	50562070
Hepatitis	15.44	10.45	59	41674	31394	50531997
Hepatic failure	15.39	10.45	60	41673	32223	50531168
Therapeutic product effect decreased	15.31	10.45	59	41674	135991	50427400
Hepatic enzyme increased	15.19	10.45	60	41673	137320	50426071
Acute respiratory distress syndrome	15.17	10.45	45	41688	21054	50542337
Hypovolaemic shock	15.12	10.45	20	41713	5168	50558223
Intentional product misuse	15.06	10.45	10	41723	46724	50516667
Hydronephrosis	15.00	10.45	26	41707	8515	50554876
Fluid retention	14.81	10.45	12	41721	50637	50512754
Adverse event	14.60	10.45	9	41724	43754	50519637
Device expulsion	14.57	10.45	3	41730	28819	50534572
Tonsillar hypertrophy	14.52	10.45	9	41724	857	50562534
Human herpesvirus 6 infection reactivation	14.43	10.45	5	41728	122	50563269
Genital burning sensation	14.41	10.45	6	41727	245	50563146
Pain in extremity	14.26	10.45	150	41583	272715	50290676
White blood cell count decreased	14.20	10.45	153	41580	116569	50446822
No adverse event	14.14	10.45	5	41728	33573	50529818
Rash pruritic	13.96	10.45	77	41656	47769	50515622
Headache	13.95	10.45	315	41418	506220	50057171
Osteoporosis	13.93	10.45	10	41723	44869	50518522
Genital ulceration	13.89	10.45	7	41726	446	50562945
Hip arthroplasty	13.75	10.45	4	41729	30425	50532966
Blood pressure systolic increased	13.74	10.45	6	41727	35443	50527948
Disseminated intravascular coagulation	13.73	10.45	38	41695	17097	50546294
Areflexia	13.63	10.45	14	41719	2766	50560625
Rash	13.41	10.45	463	41270	437008	50126383
Unevaluable event	13.37	10.45	11	41722	46055	50517336
Rectal haemorrhage	13.29	10.45	65	41668	38493	50524898
Blood sodium decreased	13.25	10.45	43	41690	21104	50542287
Plasma cell myeloma	13.17	10.45	56	41677	31266	50532125
Atelectasis	13.17	10.45	39	41694	18231	50545160
Dialysis	13.15	10.45	26	41707	9412	50553979
Haemorrhoids	13.10	10.45	40	41693	19013	50544378
Altered visual depth perception	13.08	10.45	6	41727	310	50563081
Red blood cell sedimentation rate increased	13.05	10.45	4	41729	29412	50533979
Muscle haemorrhage	12.90	10.45	14	41719	2944	50560447
Hiccups	12.85	10.45	11	41722	1728	50561663
Tremor	12.78	10.45	148	41585	114755	50448636
HIV wasting syndrome	12.78	10.45	3	41730	16	50563375
Nasal congestion	12.73	10.45	14	41719	51106	50512285
Axillary vein thrombosis	12.66	10.45	6	41727	334	50563057
Mucosal inflammation	12.66	10.45	66	41667	40076	50523315
Cytomegalovirus test positive	12.61	10.45	13	41720	2579	50560812
Condition aggravated	12.57	10.45	171	41562	296887	50266504
Lip ulceration	12.49	10.45	11	41722	1794	50561597
Ocular hyperaemia	12.48	10.45	41	41692	20251	50543140
Haemoglobin decreased	12.48	10.45	160	41573	127056	50436335
Graft versus host disease	12.48	10.45	20	41713	6146	50557245
Blood lactate dehydrogenase increased	12.46	10.45	40	41693	19522	50543869
Left ventricular dysfunction	12.36	10.45	27	41706	10479	50552912
Crepitations	12.35	10.45	20	41713	6199	50557192
Drug hypersensitivity	12.26	10.45	282	41451	250728	50312663
Vaginal ulceration	12.18	10.45	6	41727	364	50563027
Blood folate decreased	12.12	10.45	7	41726	586	50562805
Fluorosis	12.08	10.45	3	41730	21	50563370
Dermatitis allergic	12.02	10.45	30	41703	12690	50550701
Pleural effusion	11.95	10.45	111	41622	81343	50482048
Renal tubular acidosis	11.94	10.45	10	41723	1524	50561867
Hypersensitivity pneumonitis	11.94	10.45	12	41721	2310	50561081
Swollen tongue	11.90	10.45	51	41682	28579	50534812
Cushing's syndrome	11.54	10.45	7	41726	641	50562750
Excessive eye blinking	11.40	10.45	8	41725	938	50562453
Leukoencephalopathy	11.37	10.45	15	41718	3868	50559523
Petechiae	11.29	10.45	29	41704	12483	50550908
Clostridium difficile infection	11.10	10.45	46	41687	25393	50537998
Refusal of treatment by patient	11.07	10.45	17	41716	5036	50558355
Lung infiltration	11.03	10.45	30	41703	13363	50550028
Rash macular	11.02	10.45	38	41695	19239	50544152
Abscess rupture	10.94	10.45	5	41728	256	50563135
Liver transplant	10.93	10.45	11	41722	2121	50561270
Defaecation urgency	10.93	10.45	13	41720	3020	50560371
Resorption bone increased	10.92	10.45	8	41725	1003	50562388
Enterococcal infection	10.84	10.45	20	41713	6878	50556513
Unresponsive to stimuli	10.83	10.45	52	41681	30557	50532834
Product use in unapproved indication	10.74	10.45	54	41679	115765	50447626
Acute febrile neutrophilic dermatosis	10.65	10.45	12	41721	2630	50560761
Memory impairment	10.56	10.45	32	41701	79328	50484063
Asthma	10.53	10.45	38	41695	89299	50474092
Intentional self-injury	10.52	10.45	3	41730	23109	50540282
Arteritis	10.46	10.45	6	41727	496	50562895

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	154.42	11.18	272	35774	61120	29477361
Off label use	145.72	11.18	94	35952	300706	29237775
Drug ineffective	138.18	11.18	144	35902	363026	29175455
Pyrexia	137.77	11.18	702	35344	286920	29251561
Acute kidney injury	121.74	11.18	640	35406	264627	29273854
Death	98.02	11.18	167	35879	341917	29196564
Neutropenia	88.60	11.18	356	35690	131355	29407126
Stevens-Johnson syndrome	87.11	11.18	104	35942	16393	29522088
Blood creatinine increased	85.78	11.18	263	35783	84839	29453642
Immune reconstitution inflammatory syndrome	83.32	11.18	72	35974	7730	29530751
Pancytopenia	81.94	11.18	255	35791	82913	29455568
Cytomegalovirus infection	78.91	11.18	118	35928	23097	29515384
Completed suicide	78.61	11.18	9	36037	90237	29448244
Product dose omission issue	78.25	11.18	12	36034	96371	29442110
Hepatic cytolysis	77.17	11.18	71	35975	8276	29530205
Transplant rejection	65.75	11.18	68	35978	9144	29529337
Kidney transplant rejection	48.72	11.18	51	35995	6954	29531527
Agranulocytosis	48.33	11.18	88	35958	20252	29518229
Product use issue	47.74	11.18	4	36042	51440	29487041
Fatigue	45.07	11.18	216	35830	316605	29221876
Pneumocystis jirovecii pneumonia	42.95	11.18	75	35971	16704	29521777
Renal tubular necrosis	41.98	11.18	68	35978	14247	29524234
Leukopenia	41.74	11.18	155	35891	55048	29483433
Aspartate aminotransferase increased	41.30	11.18	163	35883	59562	29478919
Blood lactate dehydrogenase increased	40.53	11.18	79	35967	19130	29519351
Product use in unapproved indication	39.41	11.18	29	36017	86846	29451635
Pre-engraftment immune reaction	38.76	11.18	11	36035	88	29538393
Hepatitis	37.37	11.18	80	35966	20703	29517778
Cholestasis	37.34	11.18	86	35960	23376	29515105
Haemodialysis	37.30	11.18	53	35993	9901	29528580
Blood bilirubin increased	37.16	11.18	108	35938	33785	29504696
Alanine aminotransferase increased	37.10	11.18	178	35868	70766	29467715
Lymphocyte count decreased	36.77	11.18	76	35970	19195	29519286
Hospitalisation	36.68	11.18	6	36040	45982	29492499
Thrombocytopenia	36.46	11.18	285	35761	134538	29403943
Intentional product use issue	35.14	11.18	5	36041	42493	29495988
Inappropriate schedule of product administration	35.03	11.18	6	36040	44466	29494015
Osteoporotic fracture	31.84	11.18	18	36028	973	29537508
Blood urea increased	31.22	11.18	90	35956	28022	29510459
Rash maculo-papular	30.17	11.18	81	35965	24208	29514273
Rash	29.88	11.18	358	35688	189461	29349020
Toxicity to various agents	29.81	11.18	110	35936	173551	29364930
Aplasia pure red cell	29.61	11.18	35	36011	5456	29533025
Toxic skin eruption	29.50	11.18	47	35999	9710	29528771
Peripheral swelling	29.26	11.18	21	36025	63718	29474763
Cellulitis enterococcal	28.30	11.18	8	36038	63	29538418
Weight increased	28.29	11.18	31	36015	76636	29461845
Fall	28.00	11.18	116	35930	177062	29361419
Cerebrovascular accident	27.40	11.18	32	36014	76879	29461602
Encephalitis viral	27.08	11.18	17	36029	1115	29537366
Liver transplant rejection	26.91	11.18	21	36025	1953	29536528
HIV infection	26.42	11.18	17	36029	1164	29537317
Hepatitis cholestatic	26.27	11.18	37	36009	6856	29531625
Blood antidiuretic hormone increased	25.48	11.18	7	36039	49	29538432
Aspergillus infection	25.41	11.18	46	36000	10535	29527946
Dialysis	25.31	11.18	45	36001	10163	29528318
Tubulointerstitial nephritis	25.18	11.18	62	35984	17581	29520900
Pneumonia cytomegaloviral	25.15	11.18	23	36023	2659	29535822
Blood alkaline phosphatase increased	25.11	11.18	84	35962	28322	29510159
Drug reaction with eosinophilia and systemic symptoms	24.94	11.18	83	35963	27909	29510572
Intentional overdose	24.82	11.18	8	36038	38520	29499961
Rash morbilliform	24.60	11.18	22	36024	2471	29536010
Intentional product misuse	24.55	11.18	6	36040	34655	29503826
Therapeutic product effect incomplete	23.88	11.18	9	36037	39296	29499185
Blood potassium increased	23.63	11.18	54	35992	14597	29523884
Kaposi's sarcoma	23.31	11.18	14	36032	848	29537633
Graft versus host disease	23.30	11.18	42	36004	9586	29528895
Acquired immunodeficiency syndrome	23.08	11.18	11	36035	416	29538065
Liver function test abnormal	22.52	11.18	82	35964	28836	29509645
Renal failure	22.42	11.18	232	35814	118367	29420114
Hepatosplenomegaly	22.24	11.18	25	36021	3692	29534789
Lymphocele	22.24	11.18	16	36030	1316	29537165
Jaundice	21.91	11.18	82	35964	29214	29509267
Foetal exposure during pregnancy	21.87	11.18	7	36039	33860	29504621
Renal papillary necrosis	21.86	11.18	8	36038	153	29538328
Asthma	21.86	11.18	7	36039	33842	29504639
Culture urine positive	21.81	11.18	15	36031	1148	29537333
Bone marrow failure	21.51	11.18	78	35968	27371	29511110
Platelet count decreased	21.34	11.18	208	35838	104464	29434017
Neutrophil count decreased	21.11	11.18	107	35939	43460	29495021
Leukaemia recurrent	20.76	11.18	16	36030	1461	29537020
Motion sickness	20.61	11.18	8	36038	181	29538300
Hepatomegaly	20.49	11.18	39	36007	9278	29529203
Injection site pain	20.44	11.18	7	36039	32439	29506042
White blood cell count decreased	20.22	11.18	172	35874	83190	29455291
Nasopharyngitis	20.01	11.18	26	36020	59639	29478842
Human herpesvirus 6 infection	19.50	11.18	17	36029	1846	29536635
Wrong technique in product usage process	19.42	11.18	7	36039	31421	29507060
Mental status changes	19.24	11.18	89	35957	34838	29503643
Therapeutic product effect decreased	19.18	11.18	6	36040	29445	29509036
Dyspnoea	19.09	11.18	282	35764	326450	29212031
Myocardial infarction	18.81	11.18	70	35976	110226	29428255
Plasma cell myeloma	18.58	11.18	92	35954	37023	29501458
Treatment failure	18.54	11.18	11	36035	36928	29501553
Gamma-glutamyltransferase increased	18.49	11.18	73	35973	26664	29511817
Biopsy liver abnormal	18.48	11.18	7	36039	148	29538333
Joint swelling	18.38	11.18	20	36026	49610	29488871
Enterovirus infection	18.32	11.18	11	36035	666	29537815
Serum sickness	18.26	11.18	16	36030	1749	29536732
Dermatitis exfoliative	18.13	11.18	30	36016	6395	29532086
Lung infiltration	17.45	11.18	42	36004	11737	29526744
Drug intolerance	17.36	11.18	20	36026	48359	29490122
Ureteric obstruction	17.23	11.18	13	36033	1150	29537331
Chills	17.22	11.18	147	35899	71153	29467328
Syncope	17.12	11.18	47	35999	81324	29457157
Oesophageal candidiasis	16.82	11.18	22	36024	3799	29534682
Viral test positive	16.61	11.18	7	36039	197	29538284
Phlebitis	16.38	11.18	21	36025	3555	29534926
Toxic epidermal necrolysis	16.32	11.18	54	35992	18099	29520382
Culture stool positive	16.20	11.18	7	36039	210	29538271
Vena cava injury	16.17	11.18	7	36039	211	29538270
Chronic lymphocytic leukaemia	16.12	11.18	21	36025	3612	29534869
Renal tubular acidosis	16.01	11.18	15	36031	1788	29536693
Suicide attempt	15.96	11.18	11	36035	34099	29504382
Dizziness	15.96	11.18	151	35895	189533	29348948
Hepatic steatosis	15.78	11.18	47	35999	14899	29523582
SARS-CoV-2 antibody test positive	15.72	11.18	7	36039	226	29538255
Rheumatoid arthritis	15.54	11.18	10	36036	32142	29506339
Idiopathic pneumonia syndrome	15.35	11.18	7	36039	239	29538242
Cytomegalovirus chorioretinitis	14.81	11.18	19	36027	3219	29535262
Photosensitivity reaction	14.79	11.18	34	36012	9224	29529257
Complications of transplanted kidney	14.73	11.18	21	36025	3933	29534548
Rectal prolapse	14.71	11.18	7	36039	264	29538217
Lymphadenopathy	14.67	11.18	65	35981	24984	29513497
Erythema infectiosum	14.65	11.18	6	36040	157	29538324
Renal tubular disorder	14.60	11.18	22	36024	4330	29534151
Liver transplant	14.58	11.18	16	36030	2300	29536181
Parkinsonism hyperpyrexia syndrome	14.32	11.18	5	36041	83	29538398
Psoriasis	14.29	11.18	11	36035	32216	29506265
Lymphocytic infiltration	14.26	11.18	9	36037	596	29537885
HIV wasting syndrome	14.05	11.18	5	36041	88	29538393
Haemoglobin decreased	13.89	11.18	197	35849	108178	29430303
Cystic lymphangioma	13.85	11.18	3	36043	6	29538475
Blood culture positive	13.77	11.18	22	36024	4555	29533926
Lymphopenia	13.76	11.18	42	36004	13491	29524990
Dehydration	13.69	11.18	206	35840	114542	29423939
Light chain analysis decreased	13.68	11.18	4	36042	36	29538445
Acute graft versus host disease in skin	13.46	11.18	22	36024	4642	29533839
Proteus infection	13.45	11.18	10	36036	865	29537616
Wound evisceration	13.36	11.18	5	36041	102	29538379
Cytomegalovirus viraemia	13.34	11.18	26	36020	6294	29532187
Hepatitis A antibody positive	13.30	11.18	4	36042	40	29538441
Intraductal papillary mucinous neoplasm	13.20	11.18	7	36039	333	29538148
Peripheral motor neuropathy	13.18	11.18	13	36033	1652	29536829
Granulomatosis with polyangiitis	13.14	11.18	10	36036	896	29537585
Mycobacterium avium complex infection	13.13	11.18	15	36031	2254	29536227
Transplant dysfunction	13.13	11.18	15	36031	2255	29536226
Suprapubic pain	13.01	11.18	7	36039	343	29538138
Cytomegalovirus test	12.96	11.18	4	36042	44	29538437
Acute myocardial infarction	12.57	11.18	25	36021	48413	29490068
Stent removal	12.53	11.18	3	36043	11	29538470
Myositis	12.47	11.18	34	36012	10249	29528232
Rash papular	12.41	11.18	29	36017	7952	29530529
Therapeutic product effect prolonged	12.40	11.18	6	36040	235	29538246
Hepatitis B antibody positive	12.28	11.18	4	36042	53	29538428
Autoimmune haemolytic anaemia	12.27	11.18	19	36027	3829	29534652
Bronchopulmonary aspergillosis	12.26	11.18	38	36008	12306	29526175
Total lung capacity decreased	12.17	11.18	8	36038	568	29537913
Overdose	12.12	11.18	53	35993	79766	29458715
Biliary sepsis	12.12	11.18	8	36038	572	29537909
Renal cyst haemorrhage	12.06	11.18	7	36039	398	29538083
Abdominal wall haemorrhage	12.05	11.18	6	36040	250	29538231
Skin exfoliation	11.95	11.18	57	35989	22588	29515893
Immunosuppressant drug level increased	11.80	11.18	21	36025	4744	29533737
Granulomatous rosacea	11.76	11.18	5	36041	144	29538337
COVID-19	11.76	11.18	16	36030	35998	29502483
Febrile bone marrow aplasia	11.75	11.18	27	36019	7324	29531157
Enterococcal infection	11.74	11.18	29	36017	8239	29530242
Candida infection	11.70	11.18	43	36003	15182	29523299
Acute graft versus host disease in liver	11.63	11.18	11	36035	1327	29537154
Acquired haemophilia	11.56	11.18	9	36037	834	29537647
Hepatitis C virus test	11.48	11.18	4	36042	66	29538415
Laryngeal pain	11.45	11.18	15	36031	2593	29535888
Parvovirus infection	11.39	11.18	7	36039	442	29538039
Epidermal necrosis	11.28	11.18	7	36039	450	29538031
Blood pressure increased	11.21	11.18	49	35997	73754	29464727

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	257.87	10.41	980	60967	448260	63988525
Hyperkalaemia	233.42	10.41	378	61569	100751	64336034
Drug ineffective	207.29	10.41	305	61642	839942	63596843
Off label use	176.96	10.41	209	61738	632597	63804188
Pyrexia	139.48	10.41	965	60982	557679	63879106
Pre-engraftment immune reaction	138.24	10.41	37	61910	304	64436481
Stevens-Johnson syndrome	137.37	10.41	167	61780	34082	64402703
Completed suicide	136.97	10.41	25	61922	224389	64212396
Pancytopenia	117.48	10.41	353	61594	142956	64293829
Product dose omission issue	107.99	10.41	27	61920	194720	64242065
Encephalitis viral	106.57	10.41	50	61897	2330	64434455
Death	103.84	10.41	191	61756	482514	63954271
Blood creatinine increased	94.37	10.41	316	61631	135466	64301319
Drug abuse	91.82	10.41	10	61937	132364	64304421
Cytomegalovirus infection	89.77	10.41	142	61805	37057	64399728
Liver function test abnormal	85.15	10.41	181	61766	59220	64377565
Soft tissue disorder	83.25	10.41	47	61900	3229	64433556
Leukopenia	81.62	10.41	248	61699	100994	64335791
Human herpesvirus 6 infection	80.09	10.41	52	61895	4602	64432183
Immune reconstitution inflammatory syndrome	76.44	10.41	76	61871	12394	64424391
Kidney transplant rejection	75.67	10.41	67	61880	9444	64427341
Fatigue	72.36	10.41	423	61524	748307	63688478
Product use issue	71.64	10.41	28	61919	151687	64285098
Transplant rejection	71.64	10.41	86	61861	17315	64419470
Injection site pain	71.05	10.41	11	61936	111397	64325388
Hyponatraemia	63.10	10.41	296	61651	148043	64288742
Drug reaction with eosinophilia and systemic symptoms	62.98	10.41	152	61795	54065	64382720
Pneumonia viral	60.04	10.41	54	61893	7768	64429017
Lip swelling	60.00	10.41	109	61838	31798	64404987
Neutropenia	56.58	10.41	409	61538	239215	64197570
Thrombocytopenia	55.17	10.41	386	61561	223415	64213370
Swelling face	53.47	10.41	151	61796	59015	64377770
Intentional product use issue	53.26	10.41	13	61934	95351	64341434
Nasopharyngitis	52.20	10.41	67	61880	196006	64240779
International normalised ratio increased	52.11	10.41	181	61766	78986	64357799
Rash	51.53	10.41	669	61278	457880	63978905
Intentional overdose	50.74	10.41	12	61935	89932	64346853
Hepatic cytolysis	50.71	10.41	65	61882	13984	64422801
Toxicity to various agents	49.45	10.41	181	61766	363332	64073453
Renal tubular necrosis	48.71	10.41	81	61866	22029	64414756
Haemodialysis	48.00	10.41	70	61877	17007	64419778
Renal failure	47.51	10.41	318	61629	181370	64255415
Agranulocytosis	47.46	10.41	110	61837	38119	64398666
Toxic epidermal necrolysis	47.31	10.41	108	61839	37058	64399727
Fear of eating	47.20	10.41	17	61930	398	64436387
Tubulointerstitial nephritis	46.39	10.41	96	61851	30813	64405972
Pneumocystis jirovecii pneumonia	45.26	10.41	89	61858	27545	64409240
Wrong technique in product usage process	44.81	10.41	5	61942	64969	64371816
Inappropriate schedule of product administration	43.60	10.41	17	61930	92269	64344516
Rash maculo-papular	43.45	10.41	121	61826	46905	64389880
Infusion related reaction	42.94	10.41	57	61890	164410	64272375
Fall	41.99	10.41	232	61715	416594	64020191
Ureteric obstruction	41.53	10.41	27	61920	2395	64434390
Rheumatoid arthritis	40.83	10.41	59	61888	164235	64272550
Mouth swelling	40.67	10.41	36	61911	5071	64431714
Intentional product misuse	40.09	10.41	10	61937	72285	64364500
Platelet count decreased	39.98	10.41	287	61660	167424	64269361
Blood urea increased	38.25	10.41	111	61836	44042	64392743
Confusional state	38.17	10.41	401	61546	260743	64176042
Hepatitis	37.97	10.41	113	61834	45469	64391316
Alopecia	37.83	10.41	63	61884	165627	64271158
Psoriasis	37.72	10.41	11	61936	71692	64365093
Urosepsis	37.21	10.41	72	61875	22022	64414763
Abdominal discomfort	36.60	10.41	75	61872	182247	64254538
Arthropathy	35.76	10.41	38	61909	120929	64315856
Weight increased	35.46	10.41	97	61850	213251	64223534
Blood lactate dehydrogenase increased	34.48	10.41	89	61858	32989	64403796
Rash erythematous	34.46	10.41	114	61833	48519	64388266
Drug intolerance	33.91	10.41	82	61865	187910	64248875
Hospitalisation	33.68	10.41	15	61932	75192	64361593
Dialysis	33.34	10.41	59	61888	16861	64419924
Blood pressure increased	32.94	10.41	73	61874	172479	64264306
Superinfection	32.16	10.41	28	61919	3858	64432927
Alanine aminotransferase increased	32.02	10.41	236	61711	138795	64297990
Injection site erythema	31.90	10.41	14	61933	70786	64365999
Pain	31.52	10.41	360	61587	553151	63883634
Treatment failure	30.98	10.41	40	61907	116776	64320009
Suicide attempt	30.51	10.41	15	61932	70992	64365793
Blood potassium increased	30.34	10.41	73	61874	25907	64410878
Jaundice	30.26	10.41	109	61838	48403	64388382
Aspartate aminotransferase increased	29.12	10.41	206	61741	119582	64317203
Meningoencephalitis herpetic	28.65	10.41	19	61928	1742	64435043
Bronchopulmonary aspergillosis	28.31	10.41	59	61888	19026	64417759
Systemic lupus erythematosus	28.25	10.41	20	61927	77592	64359193
Blood alkaline phosphatase increased	28.21	10.41	118	61829	56161	64380624
Nasal congestion	28.16	10.41	11	61936	59647	64377138
Complications of transplanted kidney	27.69	10.41	30	61917	5405	64431380
Liver transplant rejection	27.67	10.41	23	61924	2976	64433809
Blood bilirubin increased	27.56	10.41	119	61828	57434	64379351
Hypophagia	27.34	10.41	92	61855	39495	64397290
Febrile bone marrow aplasia	27.19	10.41	43	61904	11212	64425573
Documented hypersensitivity to administered product	26.64	10.41	14	61933	834	64435951
Plasma cell myeloma	26.63	10.41	101	61846	45974	64390811
Maternal exposure during pregnancy	26.30	10.41	32	61915	95852	64340933
Blood culture positive	26.22	10.41	35	61912	7833	64428952
Deep vein thrombosis	26.21	10.41	182	61765	105000	64331785
Ejection fraction decreased	25.67	10.41	73	61874	28634	64408151
Clostridial infection	25.63	10.41	28	61919	5091	64431694
Product use in unapproved indication	25.27	10.41	86	61861	176532	64260253
Liver transplant	25.19	10.41	25	61922	4067	64432718
Clostridium test positive	25.07	10.41	25	61922	4090	64432695
Aspergillus infection	24.73	10.41	51	61896	16328	64420457
Hepatosplenomegaly	24.65	10.41	28	61919	5315	64431470
Fibromyalgia	24.64	10.41	83	61864	35648	64401137
Toxic skin eruption	24.49	10.41	56	61891	19228	64417557
Mental status changes	24.49	10.41	120	61827	61042	64375743
Serum sickness	24.44	10.41	22	61925	3167	64433618
Bone marrow failure	24.39	10.41	101	61846	47851	64388934
Pseudomonas infection	23.91	10.41	53	61894	17830	64418955
Rash morbilliform	23.81	10.41	27	61920	5114	64431671
Blood pressure systolic increased	23.54	10.41	9	61938	49444	64387341
Injection site pruritus	23.51	10.41	4	61943	37822	64398963
Synovial fluid analysis	23.31	10.41	16	61931	1553	64435232
Culture urine positive	23.07	10.41	24	61923	4127	64432658
Meningitis aseptic	23.06	10.41	28	61919	5702	64431083
Pemphigus	22.95	10.41	15	61932	60686	64376099
Influenza	22.95	10.41	42	61905	106489	64330296
Dermatitis exfoliative	22.90	10.41	38	61909	10314	64426471
Asthma	22.87	10.41	35	61912	95190	64341595
Photophobia	22.84	10.41	51	61896	17242	64419543
Tenosynovitis stenosans	22.30	10.41	17	61930	1943	64434842
Pregnancy with injectable contraceptive	22.28	10.41	7	61940	106	64436679
Renal tubular disorder	22.08	10.41	28	61919	5959	64430826
Arthralgia	21.99	10.41	296	61651	441964	63994821
Overdose	21.95	10.41	79	61868	159487	64277298
Tenderness	21.74	10.41	54	61893	19548	64417237
Lung infiltration	21.56	10.41	56	61891	20833	64415952
Injection site reaction	21.38	10.41	9	61938	46655	64390130
Haemoglobin decreased	21.16	10.41	283	61664	194780	64242005
Vulvovaginal candidiasis	21.04	10.41	17	61930	2113	64434672
Fluid retention	20.87	10.41	16	61931	59590	64377195
Graft versus host disease	20.84	10.41	43	61904	13770	64423015
Neutropenic sepsis	20.63	10.41	59	61888	23213	64413572
Renal papillary necrosis	20.58	10.41	9	61938	355	64436430
Injection site swelling	20.58	10.41	7	61940	41346	64395439
Urinary tract infection	20.38	10.41	324	61623	231272	64205513
Vomiting	20.36	10.41	682	61265	550435	63886350
Body mass index decreased	20.31	10.41	10	61937	519	64436266
Contraindicated product administered	20.26	10.41	46	61901	107783	64329002
Therapeutic product effect decreased	20.25	10.41	51	61896	115300	64321485
Blood antidiuretic hormone increased	20.15	10.41	6	61941	75	64436710
Cholestasis	20.13	10.41	91	61856	44781	64392004
Leukaemia recurrent	20.09	10.41	18	61929	2576	64434209
Aplasia pure red cell	20.07	10.41	29	61918	6985	64429800
Scleritis	19.91	10.41	19	61928	2947	64433838
Rash pruritic	19.77	10.41	108	61839	57296	64379489
Viral test positive	19.77	10.41	9	61938	391	64436394
Bacterial test positive	19.64	10.41	28	61919	6662	64430123
Parkinsonian rest tremor	19.64	10.41	8	61939	264	64436521
Hepatitis fulminant	19.52	10.41	27	61920	6247	64430538
Cellulitis enterococcal	19.51	10.41	5	61942	34	64436751
Conjunctivitis	19.42	10.41	53	61894	20301	64416484
Hepatomegaly	19.24	10.41	47	61900	16835	64419950
Rash macular	19.04	10.41	58	61889	23627	64413158
Loss of personal independence in daily activities	19.01	10.41	25	61922	72429	64364356
Refusal of treatment by patient	18.97	10.41	31	61916	8308	64428477
Sinusitis	18.93	10.41	74	61873	145854	64290931
Dehydration	18.60	10.41	302	61645	216461	64220324
Autoimmune haemolytic anaemia	18.44	10.41	28	61919	7048	64429737
Glossodynia	18.37	10.41	21	61926	64675	64372110
Clostridium difficile infection	18.26	10.41	76	61871	36087	64400698
Erythema multiforme	18.20	10.41	44	61903	15657	64421128
Colour blindness acquired	17.98	10.41	6	61941	111	64436674
Renal tubular acidosis	17.97	10.41	18	61929	2961	64433824
Cytomegalovirus test	17.80	10.41	5	61942	50	64436735
Biliary sepsis	17.61	10.41	13	61934	1415	64435370
Acquired immunodeficiency syndrome	17.59	10.41	7	61940	217	64436568
Thrombotic microangiopathy	17.55	10.41	45	61902	16610	64420175
Vena cava injury	17.41	10.41	7	61940	223	64436562
Inappropriate antidiuretic hormone secretion	17.38	10.41	54	61893	22235	64414550
Oral pain	17.34	10.41	62	61885	27431	64409354
Enterococcal infection	17.32	10.41	40	61907	13826	64422959
Chronic lymphocytic leukaemia	17.23	10.41	21	61926	4294	64432491
SARS-CoV-2 antibody test positive	16.88	10.41	7	61940	242	64436543
Culture stool positive	16.85	10.41	9	61938	554	64436231
HIV wasting syndrome	16.61	10.41	5	61942	65	64436720
COVID-19	16.56	10.41	23	61924	65117	64371668
Knee arthroplasty	16.47	10.41	3	61944	26996	64409789
Neuropathy peripheral	16.45	10.41	179	61768	117346	64319439
Allergy to chemicals	16.42	10.41	11	61936	1026	64435759
Lymphopenia	16.30	10.41	58	61889	25599	64411186
White blood cell count decreased	16.29	10.41	227	61720	157610	64279175
Blindness cortical	16.28	10.41	10	61937	803	64435982
Myocardial infarction	16.27	10.41	93	61854	165728	64271057
Osteonecrosis of jaw	16.23	10.41	9	61938	39816	64396969
Abdominal wall haemorrhage	16.21	10.41	8	61939	417	64436368
Trimethylaminuria	16.11	10.41	6	61941	155	64436630
Pain in extremity	16.10	10.41	200	61747	302885	64133900
Angiodermatitis	16.02	10.41	5	61942	74	64436711
Lymphocele	16.01	10.41	13	61934	1628	64435157
Pericarditis	15.97	10.41	22	61925	62494	64374291
Haemorrhoids	15.89	10.41	55	61892	23946	64412839
Biopsy liver abnormal	15.88	10.41	8	61939	436	64436349
Therapeutic response decreased	15.86	10.41	16	61931	52172	64384613
Antinuclear antibody	15.78	10.41	8	61939	442	64436343
Wound	15.72	10.41	31	61916	76446	64360339
Muscle twitching	15.72	10.41	47	61900	18951	64417834
Human herpesvirus 6 infection reactivation	15.69	10.41	7	61940	290	64436495
Seizure	15.63	10.41	236	61711	166656	64270129
Palmar erythema	15.54	10.41	13	61934	1697	64435088
Eosinophilia	15.45	10.41	75	61872	38001	64398784
Foaming at mouth	15.41	10.41	13	61934	1716	64435069
Angioedema	15.41	10.41	107	61840	61714	64375071
Cholecystitis chronic	15.31	10.41	30	61917	9257	64427528
Anti-cyclic citrullinated peptide antibody positive	15.29	10.41	15	61932	49547	64387238
Cataract	15.26	10.41	16	61931	51246	64385539
Enterovirus infection	15.19	10.41	12	61935	1445	64435340
Blood bilirubin unconjugated increased	15.18	10.41	10	61937	907	64435878
Drug interaction	15.15	10.41	455	61492	361628	64075157
Atelectasis	15.12	10.41	59	61888	27207	64409578
Tarsal tunnel syndrome	14.91	10.41	8	61939	497	64436288
Purpura senile	14.82	10.41	8	61939	503	64436282
Porphyria acute	14.79	10.41	9	61938	711	64436074
Erythema infectiosum	14.78	10.41	6	61941	196	64436589
Unevaluable event	14.76	10.41	16	61931	50473	64386312
Cardiac failure congestive	14.62	10.41	70	61877	130510	64306275
Purpura	14.59	10.41	43	61904	17203	64419582
Granulomatous rosacea	14.59	10.41	6	61941	203	64436582
Complications of transplant surgery	14.57	10.41	9	61938	730	64436055
HIV infection	14.56	10.41	10	61937	972	64435813
Chemotherapeutic drug level increased	14.55	10.41	7	61940	345	64436440
Hepatic failure	14.48	10.41	97	61850	55297	64381488
Rhinorrhoea	14.43	10.41	22	61925	59947	64376838
Pleuritic pain	14.39	10.41	27	61920	8069	64428716
Cytomegalovirus test positive	14.33	10.41	21	61926	5123	64431662
Tumour lysis syndrome	14.15	10.41	46	61901	19394	64417391
Pulmonary embolism	14.11	10.41	208	61739	146148	64290637
Tumour flare	14.05	10.41	9	61938	778	64436007
Hepatitis cholestatic	14.02	10.41	34	61913	12121	64424664
Myositis	14.02	10.41	41	61906	16336	64420449
Staphylococcal infection	14.01	10.41	90	61857	50588	64386197
Pneumonia cytomegaloviral	14.00	10.41	19	61928	4320	64432465
Effusion	13.96	10.41	13	61934	1955	64434830
Lung transplant rejection	13.95	10.41	11	61936	1321	64435464
Autonomic neuropathy	13.87	10.41	12	61935	1640	64435145
Vaginal ulceration	13.79	10.41	6	61941	234	64436551
Pustule	13.71	10.41	11	61936	1354	64435431
Cardiogenic shock	13.70	10.41	7	61940	32420	64404365
Wound evisceration	13.61	10.41	5	61942	124	64436661
Chronic obstructive pulmonary disease	13.60	10.41	30	61917	71018	64365767
Candida infection	13.56	10.41	63	61884	31356	64405429
Soft tissue swelling	13.52	10.41	10	61937	1092	64435693
Cystitis noninfective	13.49	10.41	10	61937	1096	64435689
Lymphocytic infiltration	13.44	10.41	11	61936	1393	64435392
Bacterial sepsis	13.42	10.41	25	61922	7432	64429353
Blood sodium decreased	13.38	10.41	60	61887	29422	64407363
Dermatitis allergic	13.10	10.41	38	61909	15071	64421714
Condition aggravated	12.98	10.41	266	61681	372160	64064625
Stress	12.91	10.41	24	61923	60510	64376275
Genital burning sensation	12.86	10.41	6	61941	276	64436509
Limb discomfort	12.84	10.41	5	61942	27170	64409615
Cerebral toxoplasmosis	12.83	10.41	12	61935	1814	64434971
Red blood cell sedimentation rate increased	12.82	10.41	7	61940	31228	64405557
Renal cyst haemorrhage	12.75	10.41	7	61940	455	64436330
Memory impairment	12.74	10.41	41	61906	85641	64351144
Osteoarthritis	12.74	10.41	26	61921	63310	64373475
Hydronephrosis	12.70	10.41	36	61911	14089	64422696
Cholelithiasis	12.69	10.41	81	61866	45425	64391360
Intentional self-injury	12.68	10.41	6	61941	29038	64407747
Pneumonia fungal	12.65	10.41	27	61920	8850	64427935
Limb reduction defect	12.64	10.41	4	61943	62	64436723
Prurigo	12.64	10.41	10	61937	1207	64435578
Petechiae	12.61	10.41	43	61904	18583	64418202
Discomfort	12.52	10.41	38	61909	80840	64355945
Renal transplant	12.50	10.41	13	61934	2235	64434550
Lung neoplasm	12.44	10.41	22	61925	6283	64430502
Bacterial infection	12.26	10.41	52	61895	24898	64411887
Drug hypersensitivity	12.24	10.41	307	61640	237508	64199277
Acute graft versus host disease	12.23	10.41	27	61920	9057	64427728
Accidental exposure to product	12.21	10.41	5	61942	26359	64410426
Pseudomembranous colitis	12.18	10.41	19	61928	4897	64431888
Haematocrit decreased	12.13	10.41	92	61855	54563	64382222
Perinephric collection	12.08	10.41	6	61941	317	64436468
Multiple sclerosis relapse	12.06	10.41	13	61934	41122	64395663
Surgery	12.05	10.41	6	61941	28207	64408578
Suicidal ideation	12.00	10.41	29	61918	66513	64370272
Prostatitis	11.95	10.41	16	61931	3590	64433195
Acute graft versus host disease in intestine	11.94	10.41	16	61931	3593	64433192
Areflexia	11.92	10.41	19	61928	4988	64431797
Lip ulceration	11.90	10.41	12	61935	1989	64434796
Oral candidiasis	11.89	10.41	49	61898	23163	64413622
Headache	11.89	10.41	403	61544	529064	63907721
Abdominal pain	11.86	10.41	388	61559	311987	64124798
Pruritus genital	11.85	10.41	9	61938	1023	64435762
Hepatitis C virus test	11.84	10.41	4	61943	77	64436708
Sleep apnoea syndrome	11.79	10.41	7	61940	29825	64406960
Tremor	11.78	10.41	204	61743	148026	64288759
Hip arthroplasty	11.74	10.41	3	61944	21348	64415437
Motion sickness	11.71	10.41	8	61939	770	64436015
Haemolytic anaemia	11.70	10.41	38	61909	16015	64420770
Idiopathic pneumonia syndrome	11.63	10.41	7	61940	542	64436243
Culture positive	11.62	10.41	9	61938	1053	64435732
Hand deformity	11.61	10.41	27	61920	62744	64374041
Drug dependence	11.58	10.41	9	61938	33303	64403482
Device expulsion	11.57	10.41	3	61944	21133	64415652
Cardio-respiratory arrest	11.45	10.41	52	61895	98341	64338444
Pulmonary arterial hypertension	11.45	10.41	5	61942	25362	64411423
Immunosuppressant drug level increased	11.43	10.41	23	61924	7236	64429549
Pancreatitis	11.41	10.41	97	61850	59510	64377275
Acute febrile neutrophilic dermatosis	11.39	10.41	15	61932	3314	64433471
Gastric disorder	11.33	10.41	7	61940	29190	64407595
Acne	11.32	10.41	4	61943	23077	64413708
Altered visual depth perception	11.25	10.41	6	61941	368	64436417
Crepitations	11.20	10.41	24	61923	7891	64428894
Rash papular	11.14	10.41	39	61908	17074	64419711
Blood chloride increased	11.12	10.41	18	61929	4785	64432000
Intraductal papillary mucinous neoplasm	11.09	10.41	7	61940	590	64436195
Bone marrow oedema	10.99	10.41	9	61938	1141	64435644
Hepatitis A antibody positive	10.97	10.41	4	61943	97	64436688
Pharyngeal cancer	10.97	10.41	3	61944	27	64436758
Hepatitis B antibody positive	10.94	10.41	4	61943	98	64436687
Splenomegaly	10.90	10.41	40	61907	17921	64418864
Swollen tongue	10.87	10.41	64	61883	34890	64401895
Mycobacterium avium complex infection	10.85	10.41	16	61931	3924	64432861
Liver disorder	10.84	10.41	88	61859	53263	64383522
Parkinsonism hyperpyrexia syndrome	10.82	10.41	5	61942	225	64436560
Suprapubic pain	10.81	10.41	8	61939	874	64435911
Therapeutic product effect incomplete	10.71	10.41	57	61890	103425	64333360
Hypovolaemia	10.70	10.41	36	61911	15450	64421335
Blood pressure fluctuation	10.68	10.41	21	61926	51850	64384935
Hepatic enzyme increased	10.64	10.41	77	61870	129866	64306919
Photosensitivity reaction	10.63	10.41	40	61907	18133	64418652
Herpes simplex	10.62	10.41	28	61919	10508	64426277
Genital ulceration	10.61	10.41	7	61940	636	64436149
Sepsis	10.60	10.41	293	61654	230048	64206737
Feeling abnormal	10.54	10.41	80	61867	133522	64303263
Abdominal tenderness	10.52	10.41	26	61921	9379	64427406
Infection	10.52	10.41	242	61705	184638	64252147
Graft complication	10.49	10.41	7	61940	649	64436136
Product quality issue	10.43	10.41	8	61939	29791	64406994

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01EA01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Trimethoprim and derivatives
ATC	J01EE01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives
ATC	J01EE02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives
ATC	J01EE03	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives
ATC	J01EE04	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives
ATC	J01EE05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives
ATC	J01EE07	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives
ATC	J04AM08	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
FDA MoA	N0000000191	Dihydrofolate Reductase Inhibitors
FDA EPC	N0000175489	Dihydrofolate Reductase Inhibitor Antibacterial
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000892	Anti-Infective Agents, Urinary
MeSH PA	D000962	Antimalarials
MeSH PA	D000977	Antiparasitic Agents
MeSH PA	D000981	Antiprotozoal Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D065687	Cytochrome P-450 CYP2C8 Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005493	Folic Acid Antagonists
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
FDA MoA	N0000187061	Organic Cation Transporter 2 Inhibitors
FDA MoA	N0000187062	Cytochrome P450 2C8 Inhibitors
CHEBI has role	CHEBI:35498	diuretics
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:50683	dihydrofolic acid reductase inhibitors
CHEBI has role	CHEBI:78298	environmental contaminants
CHEBI has role	CHEBI:88188	allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Shigellosis	indication	36188001
Klebsiella cystitis	indication	60867007
Urinary tract infectious disease	indication	68566005
Blepharoconjunctivitis	indication	68659002	DOID:2456
Bacterial conjunctivitis	indication	128350005	DOID:9700
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Bacterial urinary infection	indication	312124009
Infective otitis media	indication	312218008
Pneumocystosis jiroveci pneumonia	indication	415125002	DOID:11339
Acute exacerbation of chronic bronchitis	indication	425748003
Morganella Morganii Urinary Tract Infection	indication
Staphylococcus Aureus Urinary Tract Infection	indication
Haemophilus Influenzae Acute Otitis Media	indication
Pneumocystis Carinii Pneumonia Prevention	indication
Haemophilus Influenzae Chronic Bronchitis	indication
Streptococcus Pneumoniae Chronic Bronchitis	indication
Typhoid fever	off-label use	4834000	DOID:13258
Infection of skin AND/OR subcutaneous tissue	off-label use	19824006
Pertussis	off-label use	27836007
Granuloma inguinale	off-label use	28867007	DOID:9113
Nocardiosis	off-label use	29227009	DOID:2312
Listeria meningitis	off-label use	31568009	DOID:11572
Sinusitis	off-label use	36971009
Whipple's disease	off-label use	41545003	DOID:8476
Bacterial pneumonia	off-label use	53084003	DOID:874
Paracoccidioidomycosis	off-label use	59925007	DOID:12662
Cholera	off-label use	63650001	DOID:1498
Brucellosis	off-label use	75702008	DOID:11077
Paratyphoid fever	off-label use	85904008	DOID:3055
Chlamydial infection	off-label use	105629000
Infection of bone	off-label use	111253001
Meningococcus carrier	off-label use	170486006
Lymphogranuloma venereum	off-label use	186946009	DOID:13819
Chancroid	off-label use	266143009	DOID:13778
Diverticulitis of gastrointestinal tract	off-label use	271366000
Bacterial endocarditis	off-label use	301183007
Toxoplasmosis associated with acquired immunodeficiency syndrome	off-label use	421666009
Toxoplasmosis Prevention	off-label use
Postexposure Plague Prophylaxis	off-label use
Chronic Bacterial Prostatitis	off-label use
Diabetic Foot Infection	off-label use
Third trimester pregnancy	contraindication	41587001
Megaloblastic anemia due to folate deficiency	contraindication	85649008	DOID:14026
Kidney disease	contraindication	90708001	DOID:557
Anemia due to enzyme deficiency	contraindication	111577008
Deficiency of glucose-6-phosphate dehydrogenase	contraindication	124134002	DOID:2862
Folic acid deficiency	contraindication	190633005
Disease of liver	contraindication	235856003	DOID:409
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Pseudomembranous enterocolitis	contraindication	397683000
Porphyria	contraindication	418470004

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Systemic antibacterial action against sensitive organisms to surgery	Indication
Dogs	Systemic antibacterial action against sensitive organisms to debridement	Indication
Dogs	Control of bacterial infection during the treatment of acute urinary tract infections	Indication
Dogs	Control of bacterial infection during the treatment of acute bacterial complications of distemper	Indication
Dogs	Control of bacterial infection during the treatment of acute respiratory tract infections	Indication
Dogs	Control of bacterial infection during the treatment of acute alimentary tract infections	Indication
Dogs	Control of bacterial infection during the treatment of wound infections	Indication
Dogs	Control of bacterial infection during the treatment of abscesses	Indication
Horses	Systemic antibacterial action against sensitive organisms during treatment of acute strangles	Indication
Horses	Systemic antibacterial action against sensitive organisms during treatment of respiratory tract infections	Indication
Horses	Systemic antibacterial action against sensitive organisms during treatment of acute urogenital infections	Indication
Horses	Systemic antibacterial action against sensitive organisms during treatment of wound infections	Indication
Horses	Systemic antibacterial action against sensitive organisms during treatment of abscesses	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Tribrissen 120 Tablets, Tribrissen 30 Tablets, Tribrissen 480 Tablets, Tribrissen 960 Tablets	Intervet Inc.	2
Tribrissen 24% Injection	Intervet Inc.	2
Tribrissen 48% Injection	Intervet Inc.	2
Di-Trim Tablets	Zoetis Inc.	2
Tribrissen 400 Oral Paste	Intervet Inc.	2
Di-Trim 24%	Zoetis Inc.	2
Di-Trim 48% Injection	Zoetis Inc.	2
Di-Trim 400 Paste	Zoetis Inc.	2
Tribrissen 60 Oral Suspension	Intervet Inc.	2
EQUISUL-SDT	Aurora Pharmaceutical Inc.	2
Uniprim Powder	Neogen Corp.	2
Tucoprim Powder	Zoetis Inc.	2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.01	Basic
pKa2	0.6	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Dihydrofolate reductase	Enzyme	P00374	DYR_HUMAN		Ki	8	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.25	CHEMBL
Dihydrofolate reductase	Enzyme		DYR_ECOLI	INHIBITOR	IC50	5.57	CHEMBL	CHEMBL
Bifunctional dihydrofolate reductase-thymidylate synthase	Enzyme		DRTS_TOXGO		IC50	8.14	CHEMBL
Dihydrofolate reductase	Enzyme		DYR_PNECA		Ki	6.82	CHEMBL
Bifunctional dihydrofolate reductase-thymidylate synthase	Enzyme		DRTS_PLABA		IC50	6.92	CHEMBL
Bifunctional dihydrofolate reductase-thymidylate synthase	Enzyme		DRTS_PLAFK		Ki	7.99	CHEMBL
Dihydrofolate reductase	Enzyme		DYR_MOUSE		Ki	6.30	CHEMBL
Dihydrofolate reductase	Enzyme		DYR_LACCA		Ki	6.88	CHEMBL
Dihydrofolate reductase	Enzyme		DYR_YEAST		IC50	4.92	CHEMBL
Bifunctional dihydrofolate reductase-thymidylate synthase	Enzyme		DRTS_LEIMA		Ki	6.92	WOMBAT-PK
Dihydrofolate reductase	Enzyme		DYR_CANAX		IC50	8.66	CHEMBL
Dihydrofolate reductase	Enzyme		O30463_MYCAV		IC50	6.72	CHEMBL
Dihydrofolate reductase	Enzyme		B0BL08_ECOLX		Ki	8.89	CHEMBL
Bifunctional dihydrofolate reductase-thymidylate synthase	Enzyme		DRTS_TRYCR		Ki	6	WOMBAT-PK
Dihydrofolate reductase	Enzyme		DYR_STAAU		Ki	8.92	CHEMBL
Bifunctional dihydrofolate reductase-thymidylate synthase	Enzyme		DRTS_TRYBB		Ki	8	WOMBAT-PK
Dihydrofolate reductase	Enzyme		DYR_NEIGO		IC50	6.35	CHEMBL
Dihydrofolate reductase	Enzyme		DYR_LACLA		IC50	6.35	CHEMBL
Dihydrofolate reductase	Enzyme		DYR_MYCTU		IC50	4.06	CHEMBL
Dihydrofolate reductase	Enzyme		Q81R22_BACAN		Ki	4.62	CHEMBL
Bifunctional dihydrofolate reductase-thymidylate synthase	Enzyme		Q27552_CRYPV		IC50	5.40	CHEMBL
Dihydrofolate reductase type 1	Enzyme		DYR1_ECOLX		IC50	6.30	CHEMBL
Dihydrofolate reductase	Enzyme		Q8Z9J9_SALTI		Ki	8.08	CHEMBL
Dihydrofolate reductase	Enzyme		DYR_STRPN		IC50	4.38	CHEMBL
Dihydrofolate reductase	Enzyme		DYR_RAT		Ki	4.84	CHEMBL
Dihydrofolate reductase	Enzyme		Q9UUP5_PNEJI		IC50	7.04	CHEMBL

External reference:

ID	Source
4017735	VUID
N0000146103	NUI
D00145	KEGG_DRUG
56585-33-2	SECONDARY_CAS_RN
60834-30-2	SECONDARY_CAS_RN
4017735	VANDF
4019528	VANDF
C0041041	UMLSCUI
CHEBI:45924	CHEBI
TOP	PDB_CHEM_ID
CHEMBL22	ChEMBL_ID
DB00440	DRUGBANK_ID
CHEMBL2110367	ChEMBL_ID
CHEMBL1201080	ChEMBL_ID
D014295	MESH_DESCRIPTOR_UI
5578	PUBCHEM_CID
10931	IUPHAR_LIGAND_ID
1047	INN_ID
AN164J8Y0X	UNII
10829	RXNORM
3055	MMSL
5633	MMSL
5634	MMSL
d00123	MMSL
002873	NDDF
008281	NDDF
32792001	SNOMEDCT_US
387179001	SNOMEDCT_US
412323009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Polytrim	HUMAN PRESCRIPTION DRUG LABEL	2	0023-7824	SOLUTION/ DROPS	1 mg	OPHTHALMIC	NDA	19 sections
Polytrim	HUMAN PRESCRIPTION DRUG LABEL	2	0023-7824	SOLUTION/ DROPS	1 mg	OPHTHALMIC	NDA	19 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0853	SUSPENSION	40 mg	ORAL	NDA	28 sections
SULFATRIM	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0854	SUSPENSION	40 mg	ORAL	NDA	28 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	0121-4793	SUSPENSION	40 mg	ORAL	ANDA	28 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	0440-2406	TABLET	160 mg	ORAL	ANDA	13 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	0527-5180	SUSPENSION	40 mg	ORAL	ANDA	21 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	0527-5181	SUSPENSION	40 mg	ORAL	ANDA	21 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	0615-8121	TABLET	160 mg	ORAL	ANDA	26 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	0703-9503	INJECTION, SOLUTION, CONCENTRATE	16 mg	INTRAVENOUS	ANDA	22 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	0703-9514	INJECTION, SOLUTION, CONCENTRATE	16 mg	INTRAVENOUS	ANDA	22 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	0703-9514	INJECTION, SOLUTION, CONCENTRATE	16 mg	INTRAVENOUS	ANDA	22 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	0703-9526	INJECTION, SOLUTION, CONCENTRATE	16 mg	INTRAVENOUS	ANDA	22 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	0904-2725	TABLET	160 mg	ORAL	ANDA	13 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	10544-053	TABLET	160 mg	ORAL	ANDA	26 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	10544-092	TABLET	160 mg	ORAL	ANDA	25 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	10544-525	TABLET	160 mg	ORAL	ANDA	13 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	10544-926	TABLET	160 mg	ORAL	ANDA	13 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	10544-940	TABLET	160 mg	ORAL	ANDA	27 sections
Sulfamethoxazole and Trimethoprim DS	HUMAN PRESCRIPTION DRUG LABEL	2	12634-177	TABLET	160 mg	ORAL	ANDA	21 sections
SULFAMETHOXAZOLE and TRIMETHOPRIM	HUMAN PRESCRIPTION DRUG LABEL	2	12634-779	SUSPENSION	40 mg	ORAL	ANDA	21 sections
Primsol	HUMAN PRESCRIPTION DRUG LABEL	1	13551-501	SOLUTION	50 mg	ORAL	NDA	25 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	16590-210	TABLET	160 mg	ORAL	ANDA	29 sections
Polymyxin B Sulfate and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	16590-233	SOLUTION	1 mg	OPHTHALMIC	ANDA	17 sections
POLYMYXIN B SULFATE AND TRIMETHOPRIM	HUMAN PRESCRIPTION DRUG LABEL	2	17478-703	SOLUTION	1 mg	OPHTHALMIC	ANDA	19 sections
POLYMYXIN B SULFATE AND TRIMETHOPRIM	HUMAN PRESCRIPTION DRUG LABEL	2	17478-703	SOLUTION	1 mg	OPHTHALMIC	ANDA	19 sections
SULFATRIM	HUMAN PRESCRIPTION DRUG LABEL	2	17856-0007	SUSPENSION	40 mg	ORAL	NDA	21 sections
Sulfamethoxazole and Trimethoprim	Human Prescription Drug Label	2	17856-0496	SUSPENSION	40 mg	ORAL	ANDA	26 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	17856-0823	SUSPENSION	40 mg	ORAL	ANDA	20 sections
Sulfamethoxazole and Trimethoprim	HUMAN PRESCRIPTION DRUG LABEL	2	17856-5181	SUSPENSION	40 mg	ORAL	ANDA	21 sections